BR112023025188A2 - Métodos de uso de anticorpos anti-sortilina - Google Patents
Métodos de uso de anticorpos anti-sortilinaInfo
- Publication number
- BR112023025188A2 BR112023025188A2 BR112023025188A BR112023025188A BR112023025188A2 BR 112023025188 A2 BR112023025188 A2 BR 112023025188A2 BR 112023025188 A BR112023025188 A BR 112023025188A BR 112023025188 A BR112023025188 A BR 112023025188A BR 112023025188 A2 BR112023025188 A2 BR 112023025188A2
- Authority
- BR
- Brazil
- Prior art keywords
- sortilin
- methods
- antibodies
- sortilin antibodies
- matured
- Prior art date
Links
- 102100032889 Sortilin Human genes 0.000 abstract 2
- 108010014657 sortilin Proteins 0.000 abstract 2
- 101000868139 Homo sapiens Sortilin Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
métodos de uso de anticorpos anti-sortilina. a presente invenção é, de modo geral, direcionada ao uso de composições que incluem anticorpos, por exemplo, anticorpos monoclonais, quiméricos, amadurecidos por afinidade ou humanizados, fragmentos de anticorpos, etc., que se ligam especificamente a um ou mais epítopos dentro de uma proteína sortilina, por exemplo, sortilina humana ou sortilina de mamífero, e têm características funcionais melhoradas e/ou realçadas, no tratamento e/ou retardar a progressão de uma doença ou lesão em um indivíduo em necessidade dos mesmos.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208238P | 2021-06-08 | 2021-06-08 | |
| US202163209360P | 2021-06-10 | 2021-06-10 | |
| US202163225916P | 2021-07-26 | 2021-07-26 | |
| US202163277069P | 2021-11-08 | 2021-11-08 | |
| US202263304522P | 2022-01-28 | 2022-01-28 | |
| US202263311379P | 2022-02-17 | 2022-02-17 | |
| PCT/US2022/072827 WO2022261648A2 (en) | 2021-06-08 | 2022-06-08 | Methods of use of anti-sortilin antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025188A2 true BR112023025188A2 (pt) | 2024-02-27 |
Family
ID=84426402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025188A BR112023025188A2 (pt) | 2021-06-08 | 2022-06-08 | Métodos de uso de anticorpos anti-sortilina |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4351728A2 (pt) |
| BR (1) | BR112023025188A2 (pt) |
| CA (1) | CA3220428A1 (pt) |
| WO (1) | WO2022261648A2 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020007852A (es) * | 2018-01-25 | 2021-01-29 | Biogen Ma Inc | Metodos para el tratamiento de la atrofia muscular espinal. |
| AU2020291527A1 (en) * | 2019-06-11 | 2022-01-20 | Alector Llc | Anti-Sortilin antibodies for use in therapy |
-
2022
- 2022-06-08 CA CA3220428A patent/CA3220428A1/en active Pending
- 2022-06-08 WO PCT/US2022/072827 patent/WO2022261648A2/en active Application Filing
- 2022-06-08 BR BR112023025188A patent/BR112023025188A2/pt unknown
- 2022-06-08 EP EP22821249.4A patent/EP4351728A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3220428A1 (en) | 2022-12-15 |
| EP4351728A2 (en) | 2024-04-17 |
| WO2022261648A3 (en) | 2023-01-19 |
| WO2022261648A2 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| BR112021025077A2 (pt) | Anticorpos anti-sortilina para uso em terapia | |
| BR112022019892A2 (pt) | Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
| BR112018074847A2 (pt) | anticorpos específicos anti hla-g | |
| PH12019502463A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| BRPI0821658B8 (pt) | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos | |
| BR112022011570A2 (pt) | Anticorpos anti-mertk e métodos de uso dos mesmos | |
| BR112022001733A2 (pt) | Anticorpos anti-ms4a4a e métodos de uso dos mesmos | |
| MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
| MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
| MX2022004058A (es) | Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. | |
| EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
| BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
| BR112023025188A2 (pt) | Métodos de uso de anticorpos anti-sortilina | |
| BR112022011337A2 (pt) | Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo | |
| CL2022003296A1 (es) | Anticuerpos anti-cd200r1 y métodos de uso de los mismos | |
| EA201992335A1 (ru) | Антитела против сортилина и способы их применения | |
| EA201992319A1 (ru) | Анти-cd33 антитела и способы их применения | |
| EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения | |
| MX2022008745A (es) | Anticuerpos anti-nkp30 y metodos de uso. |